Our Story
A History of Discovery Science at its Highest Standards.
ID-Antigens was launched by a group of dedicated scientists with over 40 years of cumulative experience in advanced proteomics and microbiology. Powered by field-leading technical expertise in mass spectrometry proteomics, ID-Antigens is committed to revolutionizing vaccine development and arming the global biomedical community with advanced proteomics tools to combat existing as well as future diseases.
2015
Inspired by a lifetime of dedication to science and global health, ID-Antigens scientific advisor Professor David J. Gonzalez sets up his laboratory at UCSD with the premise of using high-end mass spectrometry instrumentation to perform advanced proteomics of the host-microbe interaction. Regional scientists quickly realized the power of the lab’s proteomics platform. Dr. Gonzalez launches the Collaborative Center for Multiplexed Proteomics (CCMP) in the heart of the UCSD School of Medicine.
Since its launch, CCMP has assisted researchers across the nation in answering some of the most pressing biomedical research questions spanning cancer, infectious diseases, microbiome, diabetes, and other studies.
2020
The Gonzalez lab at UCSD grows into an innovative, rigorous, productive, collaborative, and highly supportive research program. With over 70 peer-reviewed articles in the highest caliber journals, over 40 million dollars raised in federal and private sector research funding, and founding several patents, it has become a prize jewel of the UC system.
Notably, one promising antigen discovery, S protein which is implicated in several streptococcal pathogens spanning humans and other animals, leads to a patent for Professor Gonzalez and UCSD.
2023
ID-Antigens is founded by members of the Gonzalez lab (Igor Wierzbicki and Isaiah Gonzalez) UC Riverside alumni (Yesenia Rivera), and health industry expert (Aamer Mumtaz), aiming to expand upon some of the lab’s most promising discoveries, and for purposes of providing the benefits of techniques perfected at the university to academic and commercial researchers, globally.
2024
ID-Antigens initiates licensing of the S protein patent from UCSD.